Compare Amgen, Inc. (AMGN) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Trade Desk Inc — how do they compare? Amgen, Inc. trades at $359.57 (market cap $196.12B), while Trade Desk Inc trades at $20.09 (market cap $9.18B). The key difference: Amgen, Inc. is far larger — about 21.4× Trade Desk Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals.
| AMGN | TTD | |
|---|---|---|
Market Cap | $196.12B | $9.18B |
Sector | Health | Technology |
52-Week High | $388.16 | $89.76 |
52-Week Low | $271.18 | $17.33 |
Enterprise Value | $241.41B | $8.20B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
The Trade Desk (TTD) trades at $19.53, down 1.11% with bearish technical signals despite strong profitability metrics including 77.83% gross margins and 14.57% net income margin. Recent earnings show mixed results with Q1 2026 missing expectations, while revenue growth has slowed from 2024's peak. The stock faces headwinds from market share competition and a recent 52% decline in H1 2026, though analyst consensus remains positive with a $25.46 price target representing 30% upside potential.
TTD presents a value opportunity with attractive valuation multiples (P/E 22.19, P/S 3.2) and robust cash flow generation, but investors face execution risks amid slowing growth and competitive pressures. The resolution of the Publicis dispute removes a key overhang, though the stock requires sustained earnings beats and market share stabilization to justify analyst optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
